Objective: Polymyxin B (PB) is a naturally occurring cationic cyclic decapeptide which is highly bactericidal to Gram-negative bacteria. The objective of this study was to investigate the effect of PB on the viability of developing embryos during pregnancy and to validate its protective effect on the embryotoxic effect of Gram-negative bacterial lipopolysaccharide (LPS). Results: PB treatment of pregnant females disturbs the pregnancy in a dose dependent manner and increases the substantial risk of congenital abnormalities in the growing fetuses of the mother. However, PB does not show any adverse effect on implantation of embryos. The embryotoxic effect of LPS can be prevented completely by 25 µg PB/ animal; however other lower and higher doses of PB were not able to protect against the effect of LPS on pregnancy.
Introduction
Preterm labor and delivery continues to be the most important unsolved problem in obstetrics. 10-30% of women with preterm labor have clinically evident and subclinical Gramnegative bacterial infection (1) (2) (3) . The bacterial endotoxin, lipopolysaccharide (LPS), is the major antigen of the outer membrane of Gram-negative bacteria that possess a toxic effect. Gram-negative bacteria colonize in the genitourinary tract of women and contribute to creating a distinct microbial environment (4) . The endotoxins, continually released into the genitourinary tract of the infected pregnant females, may be associated with preterm labor and birth and other perinatal complications.
Several different model systems for inducing preterm labor in mice have been developed over recent years. These involve local (intrauterine or intracervical), extrauterine (e.g., renal), and systemic administration of a variety of substances, such as bacteria, bacterial products from Gram-positive and Gramnegative organisms, inflammatory cytokines, prostaglandins, and others (5) . The use of killed bacteria, components of the cell wall (LPS or Lipoteichoic acids) or proinflammatory cytokines (interleukin (IL)-1) create an inflammatory state in the absence of an overt infection. Both of these methods can promote preterm delivery in rodents and non-human primates (6) . We developed a Gram-negative bacterial infection model in mouse by the systemic administration of 'minimum dose' (i.e., 250 µg/kg body weight, i.p. on day 0.5 of pregnancy) of LPS which is sufficient to cause embryonic cell death (7) and leads to implantation failure on day 5.5 of pregnancy (8) . LPS exhibits a variety of toxic and proinflammatory activities that are related to the pathogenesis of Gram-negative bacterial infection (9) (10) (11) . LPS inhibits the blastocyst implantation in mouse by modulating the level and pattern of expression of different cytokines such as tumor necrosis factor (TNF)-α, (12) IL-1 (13) and growth factors such as colony stimulating factor (CSF)-1 (7). LPS-induced DNA damage in preimplantation stage embryos and uterine cells leads to poor pregnancy outcome (14) . Polymyxin B (PB) is a naturally occurring cationic cyclic peptide isolated from Bacillus polymyxa (15, 16) . PB is highly bactericidal to Gram-negative bacteria and is considered to be one of the most efficient cell-permeabilizing compounds (17) . This capacity is due to its high-affinity binding to the lipid A moiety of LPS in Gram-negative bacteria. PB forms a heptapeptide ring by an amide bond between the C-amino group of diaminobutyric acid (DAB) at position 4 and the carboxyl group of the C-terminal, and a tripeptide tail which is attached to a small fatty acyl chain via a peptide bond. PB is an amphiphilic compound due to the presence of both a polycationic heptapeptide ring containing five positively charged DAB residues and a hydrophobic acyl chain. These positively charged DAB residues of PB interacts with the Lipid A moiety of LPS with an ensuing loss of many of the biological properties of LPS by forming a LPS-PB complex (18) . This property of PB may be used in developing it as a novel anti-Gram-negative bacterial drug. However, the therapeutic applications of PB are very limited because of its relatively high toxicity (19, 20) . In the field of reproductive medicine, PB has been used as a chemotherapeutic drug in some gynecological pathologies, for treating pregnant females suffering from severe pyelonephritis, endometriosis, tubular obstruction in fallopian tubes and genital tract infections caused by Gram-negative bacteria (21) . It has been reported that exposure of mothers to PB in the first trimester of pregnancy does not lead to any congenital abnormalitie (21) . However, the use PB during pregnancy is debatable as to whether use of PB as an antagonist of LPS should be promoted or not. Here we investigate the effects of PB on developing embryos and pregnancy outcomes in a Gram-negative bacterial infection mouse model.
Materials and Methods

Animals
Park strain mice (6-7 weeks, ~ 20-21 g) used in the study was maintained in our animal care facility at 25±2°C with 12:12 hr light: dark period. They were regularly fed with pelleted diet (Amrut Laboratory Animal Feed, Pranav Agro Industries, Sangli, MH, India) and drinking water ad libitum. Normal mature adult females were selected for the present study. This study was conducted in accordance with the institutional ethics committee guidelines for the care and use of animals in research.
Design of experiment
The reproductive cycle was checked and females in proestrus were caged individually overnight with proven fertile male for mating. Vaginal plug was checked next day morning at 9:00 A.M. and the vaginal plug positive females were considered as being on day 0.5 of pregnancy.
Determination of the effect of PB on implantation
The effect of PB on the implantation of blastocysts was evaluated. Females were divided into two groups of five animals each. The animals of group I received 100 µl of sterile normal saline as a control and group II received 100 µg PB/animal (InvivoGen, California, USA) in a 100 µl volume through i.p. route on day 0.5 of pregnancy. Pontamine Blue dye test was performed on day 5.5 of pregnancy to observe the effect of this dose on implantation.
Determination of the effect of PB on post Implantation period of pregnancy Pregnant females were divided into five groups of six animals each. Different doses of PB (5, 25, 50 and 100 µg, i.p.) were given to individual groups on day 0.5 of pregnancy. Control animals received 100 µl of normal saline in a similar manner. The effect of PB on the status of pregnancy was assessed on days 9.5 and 14.5 of pregnancy by examining individual uterine horns and gestational sacs for live (pink, round, uniform) and dead (abnormally shaped, hemorrhagic sacs) pups and for resorption (very small, pale and gray sacs with no discernible fetus). Five pregnant females of control and 100 µg PB-treated groups were maintained up to the day of parturition to monitor the effect of PB on development of the implants during the post implantation period of pregnancy.
Determination of PB dose effective in preventing the embryotoxic effect of LPS Pregnant females were divided into six groups of four animals each. The animals of group I received sterile normal saline, group II received LPS (5 µg/animal), group III received LPS and PB (5 µg/ animal), group IV received LPS and PB (25 µg/ animal), group V received LPS and PB (50 µg/ animal) and group VI received LPS and PB (100 µg/ animal) i.p. in 100 µl volume on day 0.5 of pregnancy. The dose of LPS was the same i.e., 5 µg/ animal in each LPS and PB treated group. Status of pregnancy was assessed on day 14.5 of pregnancy. Five pregnant females of group I, II and IV were maintained up to the day of parturition to check that normal gestational sacs observed on day 14.5 of pregnancy develop into normal pups or not.
Histopathologic analysis of uterus on day 14.5 of pregnancy in animals treated with LPS and different doses of PB Histopathologic analysis of uterine horns was carried out according to a standard procedure (22) . Uterus of selected groups was collected on day 14.5 of pregnancy and fixed in Bouin's fixative for 22-24 hours. The fixed tissues were processed in a tissue processor (Leica Tissue Processor 1020, Leica Microsystems, Wetzlar, Germany) and embedded in the paraffin wax at 60°C with the use of tissue embedder (Leica Tissue Embedder, Wetzlar, Germany). Tissue blocks were sectioned at 4.5 µm using a microtome (Leica EG 1106 Microtome, Semi automated, Microm, Wetzlar, Germany). Tissue ribbons were processed in an autostainer (Leica Autostainer XL, Wetzlar, Germany) and stained with Hematoxylin and Eosin. Slides were mounted with DPX and observed under a light microscope (Leica DM IL, Wetzlar, Germany) at X5 magnification and photographed.
Statistical analyses
The results of all the experiment were analyzed by using one way analysis of variance (ANOVA) with Duncan's multiple range test for comparison of the significance level (P) among control and treated values. p<0.05 was considered to be a significant difference among the values compared.
Results
Effect of PB on implantation
The effect of PB on implantation was assessed by the presence of positive Pontamine Blue sites in uterine horns on day 5.5 of pregnancy. Uterine horns were recovered from control ( Figure  1A ) and 100 µg PB-treated ( Figure 1B ) animals on day 5.5 of gestation. No significant difference was observed in the number of implantation sites between control (9.45±0.48) and PB-treated (9.33±0.88) animals on day 5.5 of pregnancy (Table 1) . However, overcrowded conceptus with abnormal spacing was observed on day 5.5 on pregnancy as compared to controls.
Effect of PB on post-implantation period of pregnancy
The effect of PB (100 µg/animal) on the viability of embryos was assessed by examining the gestational sacs for live and dead pups and resorption during the post-implantation period of pregnancy. The uterine horns were recovered from control ( Figure 1C ) and 100 µg PB-treated animals ( Figure 1D ) on day 9.5 of gestation. No significant difference was observed between the number of gestational sacs present in control (9.41±0.41) and 100 µg PB-treated (8.50±0.50) animals on day 9.5 of gestation (Table 1) . The effect of PB was checked on the viability of embryos on day 14.5 of gestation. Uterine horns were recovered from control ( Figure 2A ) and 100 µg PB-treated animals ( Figure 2F ) on day 14.5 of gestation. A significantly lower number of normal gestational sacs were observed in 100 µg PB-treated animals (2.50±1.07) compared to the controls (8.58±0.23) ( Table 1) . Developmentally normal gestational sacs with no sign of dead pups and resorptions were recovered from the control animals ( Figure 2K ), whereas only 29.14±12.46% of gestational sacs were normal in 100 µg PB-treated animals ( Figure 2K ) on day 14.5 of pregnancy. The animals treated with normal saline and 100 µg PB was kept up to the day of parturition to check the delivery outcome. No pups were recovered from 100 µg PB-treated animals, whereas normal pups were observed in control animals (8.5±0.19) ( Table 1 ). This observation clearly suggests that the gestational sacs, which were normal on day 14.5 of pregnancy in 100 µg PB-treated animals, had undergone resorption during the later stages of development. The effect of lower doses of PB (i.e., 5, 25 and 50 µg PB/animal) on pregnancy was evaluated by visual examination of uterine horns and individual gestational sacs on day 14.5 of pregnancy. We found that percentages of normal gestational sacs were only 66.04±21.63% in 5 µg PB-treated animals ( Figure 2C, 2K) , 40.79±13.87% in 25 µg PB-treated animals ( Figure 2D, 2K) and 43.03±14.36% in 50 µg PB-treated animal (Fig. 2E, 2K ). Present observations show that PB treatment in pregnant females disturbs the normal pregnancy in a dose dependent manner and increased the substantial risk of congenital abnor- 
Effect of PB on LPS
The effect of PB in LPS-treated females was analyzed on day 14.5 of pregnancy by visual examination of individual gestational sacs recovered from the animals treated with normal saline, LPS and LPS with different doses of PB (i.e., 5, 25, 50 and 100 µg PB/animal). Gestational sacs were developmentally normal with no sign of dead pups and/or resorption in the control animals on day 14.5 of pregnancy (Figure 2A, 2K) . In LPS-treated animals, only 2.19±1.52% gestational sacs were normal ( Figure 2B, 2K) . Percentages of normal gestational sacs were 46.62±24.26% in LPS+5 µg PB-treated animals ( Fig. 2G, 2K ) and 94.87±3.1% in LPS+25 µg PB-treated animals ( Figure 2H , 2K). The numbers of gestational sacs were the same in uterine horns recovered from LPS+25 µg PB treated (8.00±0.00) and normal saline (8.58±0.23) treated animals ( Table 2 ). Percentages of normal gestational sacs were 25.00±12.21% in LPS+50 µg PB/animal ( Figure 2I , 2K) and 32.23.00±12.32% in LPS+100 µg PB/animal ( Figure 2J, 2K ). The present investigation showed that the embryotoxic effect of LPS can be significantly prevented with the dose of 25 µg PB/animal (p<0.05). The pregnancy outcome from the normal gestational sacs present on day 14.5 of pregnancy in control and LPS+25 µg PB-treated animals was analyzed. No significant difference was observed in the number of pups recovered from both groups ( Table 2 ). These observations show that the treatment of animals with 25 µg PB can protect the embryotoxic effect of LPS ( Figure 2K) . However, the other tested lower and higher doses of PB with LPS failed to prevent the high percentages of fetal loss. It may also be due to the embryotoxic effect of either LPS and PB or both.
Histopathologic analysis of uterus on day 14.5 of pregnancy in LPS and PB-treated animals
The histopathologic analysis of the uterus recovered from LPS + PB treated animals was carried out on day 14.5 of pregnancy to evaluate the state of development of fetus and its interaction with uterine epithelium. The cross sections of uterine horns recovered from animals treated with normal saline, LPS, 25 µg and 100 µg PB, LPS+25 µg PB and LPS+100 µg PB/animal were examined. The normal developing fetus was observed in the cross sections of uterine horns recovered from the control animals on day 14.5 of pregnancy ( Figure 3A) . The cross-sections of the uterine horns recovered from animals treated with LPS showed uterine lumen closure, hyperplasia of the luminal epithelium, few glands in stromal region, and with no ectoplacental cones ( Figure 3B ). However, the cross sections of uterine horns recovered from animals treated with 25 µg ( Figure 3C ) and 100 µg ( Figure 3E ) PB showed no fetus, reduced deciduas with none to few degenerated glands in deciduas. Moreover, the deciduas with reduced frond like villous outgrowth were observed in the cross sections of uterine horns recovered from the animals treated with 100 µg PB as compared to 25 µg PB-treated animals. The cross sections of the uterine horns recovered from LPS+25 µg PB-treated animals showed normal fetal membrane and developing fetus ( Figure 3D ) as observed in control pregnancy. However, the cross sections of uterine horns recovered from LPS+100 µg PB-treated animals displayed no fetus and deciduas as compared to control ( Figure 3F ).
Discussion
PB has been used widely for treating certain bacterial infections such as the meningial infections caused by Haemophilus influenzae, urinary tract infections of E. coli and bacteremia caused by Enterobacter aerogenes etc. and more so for treating the endotoxic or septic shock which is caused by endotoxin (18) . Endotoxin is an overwhelmingly powerful poison, the actions of which target virtually every cell-type in the susceptible animal, and in this way endotoxin evokes a multitude of biological responses. Gram-negative bacterial endotoxin can induce both local and systemic activation of immune response, and in extreme cases, this leads to septic shock. Gram-negative bacterial infections of the genito-urinary tract of pregnant women are known to cause fetal abortions or pregnancy loss (23, 24) . Some of the obstetricians recommended PB treatment in clinics for severe infection caused by Gram-negative bacteria. (21) . However, in the present study, it has been observed that PB shows embryotoxic effects during the post-implantation period of normal pregnancy and increases the substantial risk of congenital abnormalities in the developing fetus in a dose dependent manner. We have also shown that PB treatment may protect pregnancy in LPS-treated animals. The molecular mechanism involved in this process is not known. It is not even well established how PB disturbs the pregnancy, because it does not possess any specific and selective toxicity. Our observation of the Pontamine blue test on day 5.5 of pregnancy suggests that PB (100 µg) does not affect the blastocyst implantation. However; this dose leads to abortion of the developing fetus in later stages of gestation. Furthermore, treatment of other PB doses shows a very high percentage of fetal rejection in a dose dependent manner. It has been reported that PB induces hypothermia by modulating the thermoregulatory mechanism in rodents. In addition, it has been demonstrated that an i.v. injection of PB decreases the metabolic rate and heat loss response in rodents, which may be responsible for PB induced hypothermia that may lead to hemorrhagic condition in rodents (25) . It has also been reported that PB induces neuromuscular blockade and its action might be responsible for the decrease in metabolic rate, especially in skeletal muscles. The PB induced myoneural effect is due to its pre-synaptic action that inhibits the release of acetylcholine, which suggests the presence of its receptor at the pre-synaptic sites (25) . These observations suggest that PB induced pregnancy loss might be due to a reduction of metabolic rate, heat loss and neuromuscular blockade which may reduce the growth and development of embryos and uterus during pregnancy. We observed that the uterus recovered after PB treatment was abnormal, with loss of flexibility and hemorrhagic gestational sacs as compared to the normal uterus. Our histopathologic observations of uterus on 14.5 day of gestation also support that PB possesses an abortifacient property in a dose dependent manner. In the present study, we observed that 25 µg PB is efficient in protecting the effect of LPS-induced early pregnancy loss, whereas its other tested lower and higher doses failed to do so. Our studies show that the embryotoxic effect of LPS can be completely prevented by 25 µg PB/animal. It has been found that 94.87±3.1% developmentally normal gestational sacs present in the animals pre-exposed with LPS and treated with 25 µg PB/animal on day 14.5 of gestation, were able to develop into normal and healthy pups, whereas this was not observed with other lower and higher doses of PB. It has been suggested that PB binds to LPS at multiple places and neutralizes its effect. PB is a natural cationic cyclic peptide antibiotic containing a lipophilic and hydrophilic groupment (lipophobic) that binds to the lipid A region of LPS (18) . PB binds with high affinity to the lipid A portion and alters the three-dimensional conformation of the LPS molecule. The alteration in the conformation of LPS may possibly inhibit the binding of complex endotoxin-PB to CD14 receptor on monocytes and abrogate the liberation of inflammatory mediators such as the TNF-α (26). Due to this property; PB is used to prevent septic shock (27, 28) and it has been used to neutralize LPS-induced TNF-α production (26).
In addition, PB down regulates the expression of various cytokines such as TNF-α, IL-1, IL-10 (29). It has been shown that PB prevents the lethal effect of endotoxin in chick embryos, mice, dogs, goats, foals and horses (30) . PB was shown to inhibit LPS-induced intramuscular coagulation, macrophage production of interferon-γ, TNF-α, IL-1, the generalized Shwartzman reaction and LPS-mediated shock (27) . These evidences suggest that the protective property of PB against the LPS-induced embryopathy might be due to its ability to inhibit the production of LPS-induced cytokines during the preimplantation period of pregnancy and thus may prevent LPS-induced early pregnancy loss in mouse.
Our present observation suggests that 25 µg PB may be an efficient dose for the treatment of Gram-negative bacterial infection without any adverse affect on ongoing pregnancy. However, other doses of PB, with or without LPS, induce a high percentage of fetal resorption. Therefore, PB may not be recommended as a safe drug for the treatment of Gramnegative bacterial infection during pregnancy, because other studied doses are not effective and are even associated with fetal resorption. However, more work is being carried out in our laboratory to determine the mechanism of action of PB during pregnancy. The outcome of the investigation may provide a deeper insight to our current understanding about the roles of the antibiotic as a chemotherapeutic drug for the treatment of women suffering from vaginitis and other urinary tract infections during pregnancy. 
